Albuminuria and cardiovascular risk

Heart Failure Clinics

Volumn 2, Issue 1, 2006, Pages 53-59

  Bogojevic, Zvezdana ^a   Bakris, George L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARVEDILOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; RAMIPRIL; VERAPAMIL;

BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; HUMAN; HYPERTENSION; META ANALYSIS; MICROALBUMINURIA; PROTEINURIA; REVIEW; SYSTEMATIC REVIEW;

ALBUMINURIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 33644922067     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.11.004     Document Type: Review

References (53)

1. G. Manjunath, H. Tighiouart, and H. Ibrahim Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community J Am Coll Cardiol 41 1 2003 47 55
2. A.V. Chobanian, G.L. Bakris, and H.R. Black Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 6 2003 1206 1252
3. United States Renal Data System Available at: http://www.USRDS.org Accessed September 15, 2005
4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative Am J Kidney Dis 39 2, Suppl 2 2002 S1 S246
5. D.C. Chua, and G.L. Bakris Is proteinuria a plausible target of therapy? Curr Hypertens Rep 6 3 2004 177 181
6. G. Bakris Proteinuria and blood pressure reduction: are they of equal importance to preserve kidney function? Curr Hypertens Rep 7 5 2005 357 358
7. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 6 2003 1011 1053
8. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 5, Suppl 2 2004 1 290
9. Clinical practice recommendations 2005 Diabetes Care 28 Suppl 1 2005 S1 S79
10. G. Eknoyan, T. Hostetter, and G.L. Bakris Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Am J Kidney Dis 42 4 2003 617 622
11. J.P. Garg, and G.L. Bakris Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease Vasc Med 7 1 2002 35 43
12. L.M. Russo, G.L. Bakris, and W.D. Comper Renal handling of albumin: a critical review of basic concepts and perspective Am J Kidney Dis 39 5 2002 899 919
13. P. Clausen, J.S. Jensen, and G. Jensen Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects Circulation 103 14 2001 1869 1874
14. N.S. Anavekar, D.J. Gans, and T. Berl Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria Kidney Int Suppl 92 2004 S50 S55
15. S.D. Sibley, J.E. Hokanson, and M.W. Steffes Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes Diabetes Care 22 7 1999 1165 1170
16. S. Bianchi, R. Bigazzi, and V.M. Campese Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications Am J Kidney Dis 34 6 1999 973 995
17. M. Roest, J.D. Banga, and W.M. Janssen Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women Circulation 103 25 2001 3057 3061
18. H.C. Gerstein, J.F. Mann, and Q. Yi Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 286 4 2001 421 426
19. E.M. Stuveling, S.J. Bakker, and H.L. Hillege C-reactive protein modifies the relationship between blood pressure and microalbuminuria Hypertension 43 4 2004 791 796
20. H. Ibsen, K. Wachtell, and M.H. Olsen Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study Kidney Int 65 92 Suppl 2004 S56 S58
21. H. Ibsen, M.H. Olsen, and K. Wachtell Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study Hypertension 45 2 2005 198 202
22. M. Nakamura, T. Onoda, and K. Itai Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan Intern Med 43 10 2004 919 925
23. R. Pedrinelli, G. Dell'Omo, and B. Di Low-grade inflammation and microalbuminuria in hypertension Arterioscler Thromb Vasc Biol 24 12 2004 2414 2419
24. F.W. Asselbergs, M.P. van den Berg, and G.F. Diercks C-reactive protein and microalbuminuria are associated with atrial fibrillation Int J Cardiol 98 1 2005 73 77
25. F. Giorgino, L. Laviola, and P.P. Cavallo Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: the EURODIAB Prospective Complications Study Diabetologia 47 6 2004 1020 1028
26. L. Vaur, P. Gueret, and M. Lievre Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study Diabetes Care 26 3 2003 855 860
27. S. Nathan, C.J. Pepine, and G.L. Bakris Calcium antagonists. effects on cardio-renal risk in hypertensive patients Hypertension 46 2005 637 642
28. J.F. Mann, H.C. Gerstein, and J. Pogue Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 8 2001 629 636
29. D. De Zeeuw, G. Remuzzi, and H.H. Parving Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 2004 921 927
30. T. Berl, L.G. Hunsicker, and J.B. Lewis Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial J Am Soc Nephrol 16 7 2005 2170 2179
31. K.A. Jamerson, G.L. Bakris, and C.C. Wun Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension Am J Hypertens 17 9 2004 793 801
32. J. Lea, T. Greene, and L. Hebert The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension Arch Intern Med 165 8 2005 947 953
33. D. De Zeeuw, G. Remuzzi, and H.H. Parving Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int 65 6 2004 2309 2320
34. M.A. Pohl, S. Blumenthal, and D.J. Cordonnier Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations J Am Soc Nephrol 16 10 2005 3027 3037
35. N. Nakao, H. Seno, and H. Kasuga Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: A COOPERATE-ABP substudy Am J Nephrol 24 5 2004 543 548
36. N. Nakao, A. Yoshimura, and H. Morita Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial Lancet 361 9352 2003 117 124
37. R.O. Estacio, B.W. Jeffers, and N. Gifford Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 2000 B54 B64
38. R.W. Schrier, R.O. Estacio, and A. Esler Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 61 3 2002 1086 1097
39. P. Gaede, P. Vedel, and N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 5 2003 383 393
40. G.L. Bakris, and M.R. Weir Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link? Am J Hypertens 9 12 Pt 2 1996 200S 206S
41. G.L. Bakris, and J.H. Stein Diabetic nephropathy Dis Mon 39 8 1993 573 611
42. G. Maschio, D. Alberti, and G. Janin Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 15 1996 939 945
43. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 9069 1997 1857 1863
44. J.T. Wright Jr, G. Bakris, and T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 19 2002 2421 2431
45. M.S. Weinberg, N. Kaperonis, and G.L. Bakris How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep 5 5 2003 418 425
46. H. Peters, and E. Ritz Dosing angiotensin II blockers-beyond blood pressure Nephrol Dial Transplant 14 11 1999 2568 2570
47. G.L. Bakris, R. Slataper, and N. Vicknair ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects J Diabetes Complications 8 1 1994 2 6
48. H. Buter, M.H. Hemmelder, and G. Navis The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide Nephrol Dial Transplant 13 7 1998 1682 1685
49. J.G. Douglas, G.L. Bakris, and M. Epstein Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med 163 5 2003 525 541
50. G.L. Bakris, M.R. Weir, and M. Secic Differential effects of calcium antagonist subclasses on markers of nephropathy progression Kidney Int 65 6 2004 1991 2002
51. P. Ruggenenti, A. Fassi, and A.P. Ilieva Preventing microalbuminuria in type 2 diabetes N Engl J Med 351 19 2004 1941 1951
52. L.Y. Agodoa, L. Appel, and G.L. Bakris Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial JAMA 285 21 2001 2719 2728
53. G.L. Bakris, V. Fonseca, and R.E. Katholi Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial JAMA 292 18 2004 2227 2236